PneumoWave, an innovator in the fight against the opioidepidemic, is proud to announce that it has achieved ISO 13485:2016 certification and has registered aversion of its technology as a Class 1 UKCA device.
UK-based startup PneumoWave devises a chest-worn smart biosensor. The biosensor captures respiratory data and the startup’s platform analyses it using machine learning algorithms
PneumoWave, an innovator in the fight against the opioid epidemic with operations in Scotland and the U.S., proudly announces the appointment of Nicola Broughton as its new Non-Executive Director.
PneumoWave, a digital therapeutics company based in Scotland and the U.S., has announced the appointment of digital medicine and MedTech pioneer Richie Bavasso as the new President of the organization and member of the Board of Directors.
PneumoWave today announced the closing of £7.5 m Series A financing which will enable clinical validation and regulatory submission of its biosensor technology platform
Today is Opioid Awareness Day. Our Chief Executive Officer and Founder Dr Bruce Henderson has written a powerful opinion piece based on his direct clinical experience treating patients. Learn more about the human cost of the opioid epidemic and the compassion that addicts deserve.
We are delighted to be featured in the Scotsman newspaper:
Digital health firm PneumoWave aiming to double workforce on back of £7.5m funding injection
Digital health company PneumoWave today announced the appointment of Dr Gary Cooney as Mental Health Lead, with responsibility for the planning and execution of addiction and other mental health-related treatment studies using PneumoWave’s technology platform for diagnosis and monitoring of respiratory changes.
Glasgow, February 28, 2022, Healthtech company PneumoWave today announced that Dundee University is commencing the clinical trial of its wearable device that aims to reduce the growing number of fatal opioid overdoses in Scotland.
Digital therapeutics company PneumoWave (formerly known as Altair Medical) announced today the use of their monitoring platform in a clinical trial led by Professor Sir John Strang at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London.